Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Benjamin Egenlauf (Heidelberg, Germany), Benjamin Egenlauf, Johanna Ohnesorge, Satenik Harutyunova, Nicola Benjamin, Christine Fischer, Yeliz Enderle, Jürgen Burhenne, Christian Nagel, Andrea Huppertz, Alexandra Carls, Walter-Emil Haefeli, Ekkehard Grünig. Pharmacokinetic interactions in different combinations of pulmonary arterial hypertension treatment. Eur Respir J 2016; 48: Suppl. 60, 2397

Member's Comments

No comment yet.

Related content which might interest you: Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Pulmonary vascular resistance and compliance relationship in pulmonary hypertension Source: Eur Respir J 2015; 46: 1178-1189 Year: 2015 Acute vasodilator response in different forms of pre-capillary pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Effect of pulmonary arterial hypertension on outcome of pulmonary tuberculosis Source: Annual Congress 2011 - Clinical tuberculosis Year: 2011 Systemic consequences of pulmonary arterial hypertension Source: International Congress 2019 – State of the art session: Pulmonary vascular diseases Year: 2019 Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Initial dual oral combination therapy in pulmonary arterial hypertension Source: Eur Respir J 2016; 47:1727-1736 Year: 2016 Switching to macitentan in pulmonary arterial hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Combined treatment in pulmonary hypertension Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine Year: 2016 Assessment of simvastatin treatment on pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1 Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 The future of treatment for pulmonary arterial hypertension Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017 The future of treatment for pulmonary arterial hypertension Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014 The future of treatment for pulmonary arterial hypertension Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 The future of treatment for pulmonary arterial hypertension Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease Year: 2012 Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed Source: Eur Respir J 2010; 36: 986-990 Year: 2010